ZTS Share Price | Zoetis, Inc. Stock Analysis & Recommendation

Q: How big is Zoetis, Inc.?

As of Jun 18, Zoetis, Inc. has a market capitalization of 76,587.16 million, categorizing it as a Large Cap company.As of Jun 18, the sum of Net Sales for the latest four quarters is 9,286.00 million, while the sum of Net Profit for the same period is 2,528.00 million.As of Dec 24, the reporting period shows Shareholder's Funds of 4,770.00 million and Total Assets amounting to 14,237.00 million.

Q: What does Zoetis, Inc. do?

Overview:Zoetis, Inc. is engaged in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines, operating within the Pharmaceuticals & Biotechnology industry and classified as a large-cap company.Financial Snapshot:Most recent Net Sales: 2,220 Million (Quarterly Results - Mar 2025)Most recent Net Profit: 631 Million (Quarterly Results - Mar 2025)Market-cap: USD 76,587.16 Million (Large Cap)Key Metrics:P/E: 31.00Dividend Yield: 82.27%Debt Equity: 1.04Return on Equity: 55.54%Price to Book: 16.45Contact Details:Address: 10 Sylvan Way, PARSIPPANY NJ: 07054-3825Tel: 1 973 8227000Website: https://www.zoetis.com/

Q: Is Zoetis, Inc. technically bullish or bearish?

As of 27 June 2025, the technical trend for Zoetis, Inc. has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include the daily moving averages indicating bearish momentum, and the weekly Bollinger Bands also confirming a bearish outlook. The MACD shows a mixed signal with a mildly bullish weekly reading but a bearish monthly perspective. Overall, the combination of these indicators suggests a prevailing bearish sentiment in the market for Zoetis, Inc.

Q: Is Zoetis, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Zoetis, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 31, a Price to Book Value of 17.32, and an EV to EBITDA of 21.76. In comparison, Eli Lilly & Co. has a higher P/E of 40.89, while Johnson & Johnson shows a lower P/E of 26.18, indicating that Zoetis is positioned competitively within its peer group.Despite the fair valuation, Zoetis has underperformed relative to the S&P 500, with a year-to-date return of -11.58% compared to the S&P 500's 13.30%. This trend continues over longer periods, with a 5-year return of -11.92% against the S&P 500's impressive 91.29%, suggesting that while the stock may be fairly valued, it faces significant challenges in generating returns compared to broader market benchmarks.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

869.5 k

Shareholding (Sep 2025)

FII

31.89%

Held by 614 FIIs

DII

35.65%

Held by 79 DIIs

Promoter

0.11%

How big is Zoetis, Inc.?

22-Jun-2025

As of Jun 18, Zoetis, Inc. has a market capitalization of $76.59 billion, with net sales of $9.29 billion and net profit of $2.53 billion over the latest four quarters.

View full answer

What does Zoetis, Inc. do?

22-Jun-2025

Zoetis, Inc. specializes in animal health medicines and vaccines, operating in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $2.22 billion and a market cap of approximately $76.59 billion.

View full answer

Who are in the management team of Zoetis, Inc.?

22-Jun-2025

As of March 2022, the management team of Zoetis, Inc. includes Non-Executive Chairman Michael McCallister, CEO Kristin Peck, and Directors Antoinette Leatherberry, Paul Bisaro, Frank D'Amelio, and Sanjay Khosla. They oversee the company's strategic direction and operations.

View full answer

Is Zoetis, Inc. technically bullish or bearish?

29-Jun-2025

As of June 27, 2025, Zoetis, Inc. is in a bearish trend with moderate strength, indicated by daily moving averages and weekly Bollinger Bands, despite a mixed MACD signal.

View full answer

Is Zoetis, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Zoetis, Inc. is fairly valued with a P/E ratio of 31, but has underperformed the S&P 500 with a year-to-date return of -11.58% compared to the index's 13.30%.

View full answer

Compare Zoetis, Inc. with Similar Stocks

Regeneron Pharmaceuticals, Inc.Vertex Pharmaceuticals, Inc.Bristol Myers Squibb Co.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

High Management Efficiency with a high ROCE of 33.61%

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.22 times

Healthy long term growth as Net Sales has grown by an annual rate of 8.16%

The company has declared Positive results for the last 6 consecutive quarters

With ROCE of 36.14%, it has a fair valuation with a 8.99 Enterprise value to Capital Employed

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 55,122 Million (Large Cap)

P/E

31.00

Industry P/E

Dividend Yield

1.65%

Debt Equity

0.92

Return on Equity

49.15%

Price to Book

10.21

Revenue and Profits:

Net Sales:

2,460 Million

(Quarterly Results - Jun 2025)

Net Profit:

718 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-27.79%

6 Months

-29.8%

1 Year

-30.63%

2 Years

-23.94%

3 Years

-23.18%

4 Years

-31.88%

5 Years

-11.34%

Zoetis, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Zoetis, Inc. Stock Plummets to New 52-Week Low of $122.00

Zoetis, Inc. has reached a new 52-week low, reflecting a 30.4% decline over the past year, contrasting with the S&P 500's positive performance. The company, with a market cap of USD 71,581 million, features a P/E ratio of 31.00 and a dividend yield of 60.56%.

Read full news article

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

8.16%

EBIT Growth (5y)

10.30%

EBIT to Interest (avg)

12.16

Debt to EBITDA (avg)

1.22

Net Debt to Equity (avg)

1.04

Sales to Capital Employed (avg)

0.77

Tax Ratio

20.90%

Dividend Payout Ratio

32.86%

Pledged Shares

Institutional Holding

97.90%

ROCE (avg)

33.61%

ROE (avg)

48.44%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

17.32

EV to EBIT

24.87

EV to EBITDA

21.76

EV to Capital Employed

8.99

EV to Sales

9.20

PEG Ratio

3.69

Dividend Yield

78.17%

ROCE (Latest)

36.14%

ROE (Latest)

55.54%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 230 Schemes (32.34%)

Foreign Institutions

Held by 614 Foreign Institutions (31.89%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 10.81% vs -4.19% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 13.79% vs 8.61% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,460.00",
          "val2": "2,220.00",
          "chgp": "10.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,112.00",
          "val2": "965.00",
          "chgp": "15.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "58.00",
          "val2": "59.00",
          "chgp": "-1.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "25.00",
          "val2": "-11.00",
          "chgp": "327.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "718.00",
          "val2": "631.00",
          "chgp": "13.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "402.00%",
          "val2": "381.10%",
          "chgp": "2.09%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 8.33% vs 5.74% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 6.67% vs 10.85% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9,256.00",
          "val2": "8,544.00",
          "chgp": "8.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3,889.00",
          "val2": "3,560.00",
          "chgp": "9.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "242.00",
          "val2": "258.00",
          "chgp": "-6.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-62.00",
          "val2": "-95.00",
          "chgp": "34.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2,496.00",
          "val2": "2,340.00",
          "chgp": "6.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "366.50%",
          "val2": "359.20%",
          "chgp": "0.73%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

2,460.00

2,220.00

10.81%

Operating Profit (PBDIT) excl Other Income

1,112.00

965.00

15.23%

Interest

58.00

59.00

-1.69%

Exceptional Items

25.00

-11.00

327.27%

Consolidate Net Profit

718.00

631.00

13.79%

Operating Profit Margin (Excl OI)

402.00%

381.10%

2.09%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 10.81% vs -4.19% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 13.79% vs 8.61% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

9,256.00

8,544.00

8.33%

Operating Profit (PBDIT) excl Other Income

3,889.00

3,560.00

9.24%

Interest

242.00

258.00

-6.20%

Exceptional Items

-62.00

-95.00

34.74%

Consolidate Net Profit

2,496.00

2,340.00

6.67%

Operating Profit Margin (Excl OI)

366.50%

359.20%

0.73%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 8.33% vs 5.74% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 6.67% vs 10.85% in Dec 2023

All Annual Results

Company CV

About Zoetis, Inc.

Zoetis, Inc.

Pharmaceuticals & Biotechnology

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.

Company Coordinates

Company Details

10 Sylvan Way , PARSIPPANY NJ : 07054-3825

Tel: 1 973 8227000

https://www.zoetis.com/

Registrar Details

Zoetis, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Zoetis, Inc.?

Watch in Real-Time

What does Zoetis, Inc. do?

Who are in the management team of Zoetis, Inc.?

Is Zoetis, Inc. technically bullish or bearish?

Is Zoetis, Inc. overvalued or undervalued?

Compare Zoetis, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

High Management Efficiency with a high ROCE of 33.61%

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.22 times

Healthy long term growth as Net Sales has grown by an annual rate of 8.16%

The company has declared Positive results for the last 6 consecutive quarters

With ROCE of 36.14%, it has a fair valuation with a 8.99 Enterprise value to Capital Employed

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Zoetis, Inc. Stock Plummets to New 52-Week Low of $122.00

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Zoetis, Inc.

Company Coordinates